Results 71 to 80 of about 22,676 (187)

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Rapid Onset Liver Injury Due to Azacitidine Through Possibly a Unique Mechanism of Hypoperfusion of the Liver

Journal of Investigative Medicine High Impact Case Reports
Azacitidine and venetoclax are important anti-neoplastic agents used in the treatment of acute myeloid leukemia. Azacitidine has been implicated to cause nonhepatic ischemic injury. Here we report a case of severe, short latency drug-induced liver injury
Dilara Hatipoglu MD, Arsia Jamali MD, MPH, Emily Sheng BA, K. Rajender Reddy MD   +3 more
doaj   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine—a prospective multicenter study by the Polish Adult Leukemia Group

Frontiers in Oncology
IntroductionInfections represent one of the most frequent causes of death of higher-risk MDS patients, as reported previously also by our group. Azacitidine Infection Risk Model (AIR), based on red blood cell (RBC) transfusion dependency, neutropenia <
Krzysztof Mądry, Karol Lis, Elzbieta Sienkiewicz, Joanna Drozd-Sokołowska, Przemysław Biecek, Oktawia Sośnia, Aleksandra Gołos, Magdalena Olszewska-Szopa, Agata Obara, Zuzanna Walkowiak, Joanna Ściesińska, Edyta Subocz, Aleksandra Butrym, Rafał Machowicz, Katarzyna Budziszewska, Grzegorz Basak   +15 more
doaj   +1 more source

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

Haematologica, 2016
Disease relapse is the most common cause of treatment failure after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes, yet treatment options for such patients remain extremely limited.
Charles Craddock, Myriam Labopin, Marie Robin, Juergen Finke, Patrice Chevallier, Ibrahim Yakoub-Agha, Jean Henri Bourhis, Henrik Sengelov, Didier Blaise, Thomas Luft, Michael Hallek, Nicolaus Kröger, Arnon Nagler, Mohamad Mohty   +13 more
doaj   +1 more source

Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis

Experimental Hematology & Oncology, 2020
Background The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carried out to compare the two agents.
Bingbing Wen, Weiwen You, Sitian Yang, Xin Du   +3 more
doaj   +1 more source

Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis.

PLoS ONE, 2022
IntroductionElderly patients with acute myeloid leukemia not eligible for intensive antileukemic therapy are treated with less intensive therapies, uncertainty remains regarding their relative merits.ObjectivesTo compare the effectiveness and safety of ...
Luis Enrique Colunga-Lozano, Fernando Kenji Nampo, Arnav Agarwal, Pinkal Desai, Mark Litzow, Mikkael A Sekeres, Gordon H Guyatt, Romina Brignardello-Petersen   +7 more
doaj   +1 more source

Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer [PDF]

, 2019
In bladder, loss of mammalian Sonic Hedgehog (Shh) accompanies progression to invasive urothelial carcinoma, but the molecular mechanisms underlying this cancer-initiating event are poorly defined.
KIM, SANGUK, Shin, Kunyoo
core   +1 more source

Clonal haematopoiesis in T‐follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution

British Journal of Haematology, EarlyView.
Summary T‐follicular helper cell lymphomas (TFHLs) are frequently associated with epigenetic mutations and clonal haematopoiesis (CH), but the clinical and prognostic implications of CH in TFHL remains unclear. We performed next‐generation sequencing on paired peripheral blood (PB) and tumour tissue samples from 30 patients with TFHL. CH was defined by
Chong Wei, Yan Zhang, Danqing Zhao, Wei Zhang, Daobin Zhou   +4 more
wiley   +1 more source